Silence Therapeutics
SLN
9.39
-0.43
-4.38%
Silence Therapeutics
US · SLN
#3615 by market cap
9.39
-0.43
-4.38%
Live - 5344 symbols - heartbeat 312s ago
· 2026-10-08 10:00
Pre-market
9.95
+1.32%
After-hours
9.82
0.00%
- Market cap
- 583.63M
- P/E (TTM)i
- -7.28
- P/Bi
- 15.17
- EPSi
- -1.89
- Div yieldi
- 0.00%
- 52W posi
- 39%
Reader sentiment
Are you bullish or bearish on SLN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -2.22, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -98.71% YoY
Margins
- Gross margin
- 61.54%
- Operating margin
- -16,055.99%
- Net margin
- -15,851.88%
Key ratios & quality
- Altman Z-Scorei
- -2.22
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 319.92K | 7.47M | 16.76M | 21.66M | 31.64M | 43.26M | 559.00K |
| Gross profit | -- | 319.92K | 2.34M | 6.69M | 8.19M | 18.78M | 31.45M | 344.00K |
| Selling & admin expenses | 13.74M | 12.64M | 19.06M | 27.00M | 25.68M | 26.22M | 26.88M | 22.34M |
| Research & development | 12.36M | 17.49M | 27.54M | 41.52M | 43.55M | 56.94M | 67.88M | 67.75M |
| Operating profit | -26.10M | -29.81M | -48.85M | -61.83M | -61.04M | -64.38M | -63.32M | -89.75M |
| Pretax profit | -26.05M | -29.99M | -49.12M | -61.89M | -49.65M | -53.27M | -44.46M | -88.60M |
| Tax | -2.68M | -4.31M | -4.76M | -8.70M | 688.00K | 956.00K | 845.00K | 11.00K |
| Net profit | -23.36M | -25.68M | -44.36M | -53.19M | -50.33M | -54.23M | -45.31M | -88.61M |
| Basic EPS | -1 | -1 | -2 | -2 | -2 | -1 | -1 | -2 |
| Diluted EPS | -1.00 | -1.03 | -1.63 | -1.79 | -1.56 | -1.47 | -0.99 | -1.89 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 142.00K | 224.00K | 159.00K | 34.00K | 422.00K | 0 |
| Gross profit | 88.00K | 139.00K | 95.00K | 22.00K | 411.00K | 0 |
| Selling & admin expenses | 7.68M | 5.13M | 5.80M | 3.73M | 7.03M | 4.72M |
| Research & development | 20.81M | 17.65M | 20.54M | 8.75M | 9.12M | 9.15M |
| Operating profit | -28.41M | -22.64M | -26.24M | -12.46M | -15.74M | -13.87M |
| Pretax profit | -28.53M | -27.34M | -20.96M | -11.77M | -14.96M | -12.27M |
| Tax | 0 | 10.00K | 1.00K | 0 | 0 | 1.00K |
| Net profit | -28.53M | -27.35M | -20.96M | -11.77M | -14.96M | -12.27M |
| Basic EPS | -1 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.60 | -0.57 | -0.45 | -0.27 | -0.33 | -0.27 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 37.43M | 49.12M | 104.12M | 116.52M | 117.01M | 103.15M | 187.37M | 118.66M |
| Cash & ST investments | 33.67M | 43.95M | 51.04M | 99.25M | 86.10M | 68.79M | 147.33M | 85.11M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 49.34M | 60.41M | 117.16M | 129.83M | 130.10M | 119.45M | 202.64M | 131.44M |
| Total current liabilities | 4.86M | 12.66M | 34.85M | 20.47M | 26.56M | 22.34M | 16.82M | 13.61M |
| Short-term debt | -- | 376.30K | 464.72K | 184.90K | 539.75K | 228.00K | 117.00K | 89.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 4,859,912.70 | 32,999,423.09 | 104,817,585.89 | 118,319,971.93 | 103,384,928.17 | 97,455,000.00 | 68,612,000.00 | 69,138,000.00 |
| Total equity | 44.48M | 27.42M | 12.35M | 11.51M | 26.71M | 21.99M | 134.02M | 62.30M |
| Retained earnings | -169.75M | -199.30M | -251.05M | -300.92M | -318.60M | -431.89M | -474.04M | -562.57M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 169.79M | 148.55M | 133.63M | 118.66M | 102.85M | 94.28M |
| Cash & ST investments | 136.53M | 114.16M | 102.19M | 85.11M | 70.08M | 72.05M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 185.30M | 165.23M | 146.79M | 131.44M | 115.12M | 106.41M |
| Total current liabilities | 19.26M | 14.77M | 17.38M | 13.61M | 10.46M | 12.71M |
| Short-term debt | 60.00K | -- | 85.00K | 89.00K | 93.00K | 103.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 298,041,000.00 | 71,078,000.00 | 72,727,000.00 | 69,138,000.00 | 65,721,000.00 | 67,941,000.00 |
| Total equity | -112.74M | 94.16M | 74.06M | 62.30M | 49.40M | 38.47M |
| Retained earnings | 502.54M | -529.84M | -550.80M | -562.57M | -577.53M | -589.63M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -21.27M | 2.26M | -14.69M | 9.19M | -57.04M | -49.46M | -67.64M | -62.27M |
| Depreciation & amortization | 506.29K | 631.98K | 675.96K | 576.29K | 596.00K | 621.00K | 593.00K | 555.00K |
| Free cash flow | -21.51M | 2.25M | -15.39M | 7.39M | -57.59M | -49.52M | -67.85M | -62.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 432.70K | 6.91M | 21.57M | 41.73M | 52.58M | 31.94M | 142.09M | 15.00K |
| Ending cash balance | 27.27M | 17.72M | 37.41M | 99.25M | 66.27M | 68.79M | 121.33M | 11.28M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -12.31M | -21.78M | -10.89M | -17.29M | -15.60M | 1.52M |
| Depreciation & amortization | 138.00K | 148.00K | 156.00K | 113.00K | 106.00K | 108.00K |
| Free cash flow | -12.31M | -21.83M | -10.89M | -17.29M | -15.60M | 1.52M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 14.00K | 1.00K | 0 | 0 | 0 | 2.00K |
| Ending cash balance | 64.89M | 41.74M | 82.03M | 11.28M | 5.66M | 72.05M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -40.55 | -71.42 | -223.11 | -445.98 | -256.42 | -227.61 | -58.18 | -90.27 |
| ROA %i | -37.78 | -46.79 | -49.96 | -43.07 | -37.70 | -44.16 | -28.13 | -53.05 |
| ROIC %i | -40.63 | -70.66 | -219.18 | -434.17 | -252.60 | -229.24 | -62.31 | -92.80 |
| 5-year avg ROE %i | -22.16 | -28.66 | -70.32 | -156.85 | -208.89 | -245.32 | -242.65 | -216.08 |
| EBIT margin %i | -- | -9,359.43 | -657.51 | -369.30 | -270.39 | -198.13 | -146.38 | -16,055.99 |
| FCF / sales %i | -- | 704.10 | -- | 44.08 | -- | -- | -- | -- |
| Current ratioi | 7.70 | 3.88 | 2.99 | 5.69 | 4.41 | 4.62 | 11.14 | 8.72 |
| Quick ratioi | 7.57 | 3.84 | 2.77 | 5.41 | 4.03 | 4.15 | 10.36 | 8.06 |
| Debt / assetsi | -- | 0.62 | 0.40 | 0.14 | 0.41 | 0.29 | 0.06 | 0.12 |
| LT debt / equityi | -- | -- | -- | -- | -- | 0.54 | -- | 0.11 |
| Interest coveragei | -- | -692.03 | -2,251.56 | -5,731.00 | -1,006.83 | -1,478.71 | -- | -- |
| Revenue CAGR (3Y) %i | 0.00 | -30.43 | 601.58 | -- | 307.54 | 61.82 | 37.18 | -70.45 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -327.48 | -66.93 | -64.37 | -90.27 | -- | -90.41 |
| ROA %i | -33.21 | -39.19 | -34.56 | -53.05 | -49.96 | -44.14 |
| ROIC %i | -325.30 | -66.93 | -64.25 | -92.80 | -- | -90.26 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -310.99 | -314.32 | -316.08 | -16,055.99 | -9,187.25 | -11,106.83 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.81 | 10.06 | 7.69 | 8.72 | 9.83 | 7.42 |
| Quick ratioi | 7.96 | 9.09 | 7.16 | 8.06 | 8.82 | 6.40 |
| Debt / assetsi | 0.03 | 0.00 | 0.12 | 0.12 | 0.12 | 0.11 |
| LT debt / equityi | -- | -- | 0.13 | 0.11 | 0.09 | 0.02 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
RNA therapeutics100.00%
Quote time 2026-10-08 10:00:12 · For reference only, not investment advice and not tailored to your situation.